Charles River Laboratories International, Inc.
CRLNYSETrackedESG Rated: 1/2 ProvidersMarket Data VerifiedHealth CareLife Sciences Tools And ServicesMSCI: 71.1 / 100
- Coverage
- Rated universe Carries an MSCI or Sustainalytics observation.
- ESG profile reviewed
- Last editorial update to this profile.
- Quote
- Delayed quoteObservation time is shown beside the price.
- Methodology
- How we rateProvider ratings are shown separately, never blended.
Market overview
Up+USD 16.46 (+5.94%) Day change
This quote can lag the exchange by several minutes. It is not a real-time price.
- Open
- USD 277.00
- Previous close
- USD 277.33
- Day high
- USD 298.23
- Day low
- USD 277.00
- Volume
- 717,198
- Market cap
- USD 14,151,197,696
View Chart Data
| Date and time | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| USD 154.22 | USD 154.94 | USD 149.91 | USD 150.25 | 786,800 | |
| USD 148.39 | USD 148.39 | USD 144.26 | USD 145.57 | 884,200 | |
| USD 167.72 | USD 175.00 | USD 165.70 | USD 170.88 | 1,906,800 | |
| USD 163.59 | USD 172.39 | USD 157.49 | USD 167.64 | 1,342,700 | |
| USD 186.80 | USD 191.34 | USD 185.93 | USD 185.99 | 1,070,100 | |
| USD 202.69 | USD 204.01 | USD 201.04 | USD 203.16 | 242,000 | |
| USD 221.22 | USD 222.29 | USD 213.46 | USD 218.82 | 743,900 | |
| USD 218.45 | USD 219.37 | USD 214.48 | USD 216.88 | 444,600 | |
| USD 183.06 | USD 183.11 | USD 162.95 | USD 165.98 | 1,979,600 | |
| USD 172.08 | USD 179.82 | USD 170.00 | USD 178.49 | 1,198,300 | |
| USD 157.67 | USD 158.51 | USD 151.68 | USD 151.97 | 791,000 | |
| USD 162.55 | USD 172.57 | USD 162.04 | USD 172.50 | 1,180,100 | |
| USD 178.94 | USD 185.00 | USD 175.79 | USD 176.94 | 915,100 | |
| USD 167.66 | USD 167.66 | USD 163.10 | USD 165.78 | 668,800 | |
| USD 157.54 | USD 160.26 | USD 149.98 | USD 150.85 | 1,397,500 | |
| USD 179.00 | USD 181.76 | USD 172.17 | USD 174.79 | 752,100 | |
| USD 188.81 | USD 191.34 | USD 181.72 | USD 182.34 | 1,025,200 | |
| USD 227.59 | USD 232.32 | USD 223.85 | USD 231.43 | 631,900 | |
| USD 215.57 | USD 223.62 | USD 213.40 | USD 219.40 | 925,000 | |
| USD 267.99 | USD 267.99 | USD 252.07 | USD 260.72 | 1,782,400 | |
| USD 284.22 | USD 294.56 | USD 280.68 | USD 290.00 | 987,400 | |
| USD 297.63 | USD 299.02 | USD 290.73 | USD 298.58 | 786,100 | |
| USD 294.21 | USD 295.77 | USD 285.56 | USD 293.35 | 646,300 | |
| USD 279.37 | USD 281.63 | USD 275.88 | USD 279.01 | 952,900 |
Company Profile & Business Model Overview
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Sustainability Strengths & Catalysts (Pros)
- Extensive animal welfare policies and investment in alternative methods: CRL publishes animal care and use policies, works to implement the 3Rs (replacement, reduction, refinement), and invests in non-animal technologies and in vitro models to reduce reli
- Global compliance and quality management infrastructure: CRL maintains broad regulatory compliance programs and quality management systems across many international sites, supporting client requirements for GLP/GCP standards and biosafety practices that h
- Environmental management and emissions reporting initiatives: CRL has set company-level environmental goals and reports on energy use, greenhouse gas emissions, and waste management in sustainability disclosures, with site-level actions to improve energy
Material Risks & Governance Concerns (Cons)
- Animal testing and ethical controversies: As a major contract research organization providing extensive animal testing and breeding services, CRL faces ongoing ethical scrutiny and reputational risk from animal welfare groups and stakeholders opposed to a
- Operational and environmental risks from laboratory activities: CRL’s global laboratory footprint entails risks related to hazardous waste, chemical and biological materials handling, and potential regulatory lapses or incidents at sites that could result
Related ESG Peer Equities
Companies in Health Care evaluated across carbon intensity, social metrics, and board governance.
ESG & Sustainability Rating Breakdown
Synthesized multi-provider rating across Environmental, Social, and Corporate Governance dimensions.
Audited Methodology
MSCI ESG industry rating benchmark.
Data integrity and methodology
MSCI and Sustainalytics ratings are shown separately with their own observation dates; they are not blended into one score, and providers can disagree. Market quotes are delayed or last-close values, and every snapshot states its source and observation time. Read the full rating methodology.
Financial & Valuation Fundamentals
Core balance sheet and equity valuation metrics sourced from corporate filings.
Audited Financials
Related ESG Financial Tools & Modeling
ESG Investment Growth Calculator
Project compound future portfolio values versus traditional index benchmarks.
Launch Tool →
Portfolio Carbon Footprint Calculator
Translate your investment capital into financed greenhouse gas emissions.
Launch Tool →
Green Mortgage Calculator
Calculate interest rate discounts on energy-efficient certified homes.
Launch Tool →
Featured Sustainable Investment Research & Guides
Top 12 Impact Investing Apps & Platforms (Reviewed)
Comprehensive review of the best ESG micro-investing and direct indexing apps.
Biblically Responsible Investing (BRI): Top Stocks & Funds
Faith-based screening criteria, ESG alignment, and values-based portfolio strategies.
Top Desalination & Clean Water Infrastructure Stocks
Invest in global clean water purification, reverse osmosis, and municipal utilities.
Best Certified B-Corp Banks & Sustainable Banking
How to align your everyday cash reserves with social and climate impact standards.
Frequently Asked Questions
Direct answers on sustainability scores, risk methodologies, and peer rankings.
What is Charles River Laboratories International, Inc. (CRL)'s ESG rating and sustainability score?
Charles River Laboratories International, Inc. (CRL) has an MSCI ESG rating of 71.1 / 100. MSCI evaluates corporate resilience to long-term industry material environmental, social, and governance risks relative to sector peers.
Is Charles River Laboratories International, Inc. considered an ESG leader or laggard in Health Care?
Independent benchmark status for Charles River Laboratories International, Inc. is evaluated relative to Health Care peers once third-party coverage publishes official methodology scores.
What are the main ESG risks and controversies for Charles River Laboratories International, Inc.?
Key material risks for Charles River Laboratories International, Inc. include: Animal testing and ethical controversies: As a major contract research organization providing extensive animal testing and breeding services, CRL faces ongoing ethical scrutiny and reputational risk from animal welfare groups and stakeholders opposed to a; Operational and environmental risks from laboratory activities: CRL’s global laboratory footprint entails risks related to hazardous waste, chemical and biological materials handling, and potential regulatory lapses or incidents at sites that could result. Investors should evaluate whether corporate mitigation plans adequately address these vulnerabilities.
How does The Impact Investor evaluate ESG stock profiles?
The Impact Investor presents audited third-party ratings from MSCI and Sustainalytics alongside delayed market data and financial fundamentals. We do not blend ratings into proprietary black-box scores, and ratings are never modified by advertising or affiliate relationships.